BREYANZI

Google image searchProduct monograph

Active ingredient

lisocabtagene maraleucel, 120000000 CELLS

DIN: 02527138

Dosage form(s): SUSPENSION

Route(s) of administration: INTRAVENOUS

Description: SINGLE DOSE VIALS - CD8 AND CD4 COMPONENTS

Schedule: Prescription / Schedule D

Company: BRISTOL-MYERS SQUIBB CANADA

Date: 19-NOV-2024

ATC:

• L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
• L01X — OTHER ANTINEOPLASTIC AGENTS (ATC, ATC/DDD)
• L01XL — Antineoplastic cell and gene therapy (ATC, ATC/DDD)
• L01XL08 — LISOCABTAGENE MARALEUCEL (ATC/DDD)

Reference brand drug: Breyanzi

External Links for Breyanzi

Search on Google

• Breyanzi side effects
• Breyanzi dosage
• lisocabtagene maraleucel side effects
• lisocabtagene maraleucel dosage

Bristol-Myers Squibb Canada

Go to Bristol-Myers Squibb website to see drug product details. Sometimes you can find breyanzi photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.